Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
56 studies found for:    S1202
Show Display Options
Rank Status Study
1 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
2 Completed Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
Condition: Advanced Non-Small Cell Lung Cancer
Intervention: Drug: S-1
3 Completed
Has Results
S0916, MLN1202 in Treating Patients With Bone Metastases
Conditions: Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: anti-CCR2 monoclonal antibody MLN1202;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
4 Recruiting S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: S-1;   Drug: Cisplatin;   Drug: Oxaliplatin
5 Unknown  Docetaxel and S-1 for Advanced Esophageal Cancer
Condition: Esophageal Neoplasms
Intervention: Drug: DS (docetaxel+S-1)
6 Recruiting A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
Condition: Biliary Tract Cancer
Intervention: Drug: Gemcitabine, S-1
7 Recruiting A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Dietary Supplement: caprylidene;   Dietary Supplement: Placebo
8 Withdrawn The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Condition: Warts
Intervention: Drug: PEP005
9 Active, not recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
10 Terminated
Has Results
AS900672-Enriched in Ovulation Induction
Condition: Ovulation Induction
Interventions: Drug: AS900672-Enriched 10 microgram (mcg);   Drug: AS900672-Enriched 20 mcg;   Drug: AS900672-Enriched 30 mcg;   Drug: AS900672-Enriched 40 mcg;   Drug: Follitropin alfa 75 international unit (IU);   Drug: Recombinant human chorionic gonadotropin (r-hCG)
11 Recruiting A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Condition: Influenza
Intervention: Drug: oseltamivir
12 Recruiting Assessment of Tremor Using SNUMAP Motion Sensing System
Condition: Tremor
Intervention: Device: SNUMAP
13 Completed
Has Results
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Conditions: Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa;   Drug: Placebo
14 Completed ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: ACT-128800;   Drug: Placebo
15 Recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
16 Completed This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
17 Recruiting Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Condition: Acute Heart Failure
Interventions: Drug: RLX030;   Drug: Placebo
18 Completed The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
19 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
20 Active, not recruiting Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate/vilanterol;   Drug: fluticasone furoate;   Drug: vilanterol;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years